A causal role for AVP in metabolic disorders is supported by preclinical evidence showing that high AVP concentration impairs glucose regulation in rats, an effect reversed by treatment with a selective V1aR antagonist [62, 63]. This evidence concerns the gene AVPR1A and metabolic disease.